AzTrials
AzTrials

Premature Ventricular ContractionsPVC-MIBGNCT02279030

Use of MIBG Scan Images in PVC Ablations

An observational study of Premature Ventricular Contractions, run by University of Maryland, Baltimore at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to assess if Single Photon Emission Computed Tomography (SPECT) demonstrating cardiac innervation can be integrated into current electrophysiology voltage mapping system and provide improved guidance for ablation of PVCs. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Premature Ventricular Contractions
What is being tested?
MIBG nuclear scan
How many people
20 participants
Where
1 siteUnited States
Study dates
Jun 2015to 31 Dec 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients requiring PVC ablation

Who may be able to join

  • Scheduled for PVC ablation

Who cannot join

  • pregnancy

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Maryland Medical Center

    Baltimore, Maryland, 21201

Other trials in United States

About this study

Official title: Three Dimensional Neuro-cardiac Imaging Using 123I-metaiodobenzylguanidine Single Photon Emission Computed Tomography to Guide Premature Ventricular Contractions Ablations

The purpose of this study is to assess if Single Photon Emission Computed Tomography (SPECT) demonstrating cardiac innervation can be integrated into current electrophysiology voltage mapping system and provide improved guidance for ablation of PVCs.

Read the detailed description

Premature ventricular contractions (PVC) are the most common arrhythmia to be observed in the absence of structural heart disease, and 'frequent' PVCs are estimated to occur in 1-4% of the general population.1 Idiopathic PVCs are usually associated with a benign course from the standpoint of arrhythmic death, but often result in significant symptoms for the patient such as palpitations, dizziness, pre-syncope and rarely syncope. More recently, a new concept of PVC- mediated cardiomyopathy has emerged that is reversible with suppression of the PVCs.2 Both of those patient populations are currently targeted with PVC suppressive therapy which often involves as the first step using medical therapy such as a beta blocker, calcium channel blocker or an antiarrhythmic. If those fail or if the patients wants to avoid medical therapy an ablation to eliminate the abnormal myocardial tissue that is the origin of the PVCs is often performed.

Radiofrequency ablation (RFA) for PVCs has been performed for several decades and has a well-defined safety and effectiveness profile in patients with symptomatic frequent ventricular ectopic beats and PVC-induced cardiomyopathy. Successful PVC suppression ≥80% of RV and LV PVCs has been reported to be as high as ~80% using an ablation approach.9 Studies found improvements in patient symptoms with elimination of PVCs. In LV dysfunction following ablation demonstrated a significant inverse correlation between EF and PVC burden before ablation, and a significant post procedural improvement in ejection fraction (EF) in 82% of patients who had abnormal systolic function before ablation.8 Improvement of the overall LV EF ranged from 13%-23% after PVC ablation.5,8,10

Autonomic innervation of the heart plays a major role in the normal regulation of myocardial function, heart rate, and coronary blood flow. Abnormal sympathetic cardiac innervation has been shown to have prognostic value for different heart diseases, e.g. heart transplant, coronary artery disease, heart failure, arrhythmias, etc. Importantly, there is a clear association with an increased cardiac morbidity and mortality in heart diseases. Patients with myocardial infarction as well as patients with heart failure exhibit well recognized abnormalities in autonomic tone. PVCs especially in the setting of preserved EF (normal heart patients) have frequently an automatic/triggered mechanism, which is influenced by the cardiac innervation.

Decreased reuptake by impaired myocardial presynaptic nerve terminals results in a buildup of these catecholamines in the synaptic cleft. This leads to a downregulation of postsynaptic beta-adrenergic receptors, with resultant worsening cardiomyopathy and increased arrhythmogenesis.

Cardiac sympathetic innervation can be directly imaged with commonly used nuclear radioisotope, 123I-meta-iodobenzylguanidine (123I-mIBG). As a norepinephrine analogue, 123I-mIBG is similarly released into the synaptic cleft in response to sympathetic input by presynaptic nerve terminals 123I-metaiodobenzylguanidine (123I-MIBG) allows visualization of the cardiac innervation, which could provide additional information to understand the origin, prognosis and pathophysiology of PVCs and guide potential ablation procedures.

Being tested
MIBG nuclear scan
Keywords
ablation
Medical subject headings
Ventricular Premature Complexes

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MIBG nuclear scanOther

    Also called PVC ablations

    To have scan to help define pathways for PVC ablations.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Utilization of MIBG imaging for PVC ablations

    To determine if MIBG imaging provides decreased PVC ablation time

    Measured: 2 years

  2. Decrease PVC occurrence

    Does MIBG imaging allow for treatment that provides improved outcomes in decreasing PVCs

    Measured: 2 years

  3. Increase in Motility

    Do MIBG follow-ups demonstrate an improvement in cardiac motility

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Oct 2014 (estimated)
  2. Study startJun 2015
  3. Primary completion31 Dec 2019
  4. Study completion31 Dec 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02279030
Sponsor's protocol ID
HP-00062156
Acronym
PVC-MIBG
Status last verified
Jan 2022
First submitted
20 Oct 2014
Last updated
8 Feb 2022
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Premature Ventricular Contractions, run by University of Maryland, Baltimore at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Utilization of MIBG imaging for PVC ablations (time frame: 2 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in